Discontinuing Lorazepam After 15 Years of Nightly Use
For a 58-year-old man on lorazepam 1 mg nightly for 15 years, discontinue using a slow taper of approximately 10–25% dose reduction every 1–2 weeks, extending the taper over several months, ideally combined with cognitive-behavioral therapy to prevent relapse and manage withdrawal symptoms. 1, 2, 3
Rationale for Slow Tapering
The FDA explicitly warns that patients at highest risk for severe withdrawal reactions are those on higher dosages and those with longer durations of use—this patient has both risk factors with 15 years of continuous use. 1
After long-term benzodiazepine use (>3 months), abrupt discontinuation or rapid dose reduction can precipitate life-threatening acute withdrawal reactions including seizures, even at therapeutic doses. 1
The required time for weaning is proportional to the duration of benzodiazepine treatment—15 years necessitates an extended taper period. 4
Specific Tapering Protocol
Initial Phase (Months 1–3):
- Reduce by 0.25 mg (25% of current dose) every 2 weeks until reaching 0.5 mg nightly. 2
- Monitor closely for withdrawal symptoms during the first 2 weeks after each dose adjustment. 5
Final Phase (Months 4–6):
- Once at 0.5 mg, reduce by 0.125 mg (approximately 10–20% reductions) every 1–2 weeks. 4, 2
- The final stages require the slowest taper as withdrawal symptoms are most pronounced when approaching complete discontinuation. 2, 6
- Consider extending dosing intervals (from nightly to every other night) in the final weeks before complete cessation. 4
Withdrawal Symptom Profile
Common withdrawal symptoms include:
- Anxiety, agitation, irritability (often appearing within 24–48 hours of dose reduction) 5, 1
- Insomnia, tremor, muscle aches, headache 2
- Sweating, tachycardia/palpitations, nausea 2
- Dizziness, sensory disturbances 6
Severe withdrawal reactions (rare but life-threatening):
- Seizures, delirium, hallucinations, suicidal ideation 1
Protracted withdrawal syndrome:
- Anxiety, cognitive impairment, insomnia, motor symptoms, and paresthesia can persist for weeks to more than 12 months after complete discontinuation. 1
Distinguishing Withdrawal from Relapse
Withdrawal symptoms are transient (typically 1–3 days per dose reduction with gradual taper), more intense than baseline anxiety, and appear rapidly after dose reduction. 5
Relapse of underlying anxiety disorder emerges more gradually and represents a return to pre-treatment symptom levels. 5
This distinction is critical: withdrawal symptoms should not automatically trigger resumption of benzodiazepines or be misinterpreted as treatment failure. 6, 7
Cognitive-Behavioral Therapy Integration
Combining slow taper with psychological support significantly improves outcomes:
Slow tapering plus psychological support (such as cognitive-behavioral therapy or mindfulness-based cognitive therapy) achieves successful discontinuation rates of 40–75% and is as effective as antidepressant continuation in preventing relapse. 3, 7
Psychological interventions should address cognitive appraisals of threat from symptoms and enhance coping competence without medication. 8
The psychological treatment must continue through completion of the taper and extend beyond it to address potential relapse of the underlying anxiety disorder. 8, 9
Monitoring and Support Strategy
Schedule follow-up visits every 2–4 weeks during the taper to assess withdrawal symptoms, anxiety levels, and adherence. 2
Educate the patient about benzodiazepine dependence, expected withdrawal symptoms, and the difference between withdrawal and relapse. 8, 10
Provide reassurance that withdrawal symptoms, while uncomfortable, are transient and manageable with proper support. 6
If withdrawal symptoms become intolerable at any dose reduction, hold at the current dose for an additional 1–2 weeks before attempting further reduction. 2
Pharmacological Adjuncts (Limited Evidence)
Transient use of hydroxyzine 25–50 mg during taper may reduce anxiety and withdrawal symptoms, though evidence is limited to short-term lorazepam users. 10
This approach is not well-studied in 15-year users and should be considered only if withdrawal symptoms are severe despite slow taper. 10
Common Pitfalls to Avoid
Do not use a 4-week or shorter taper—this is appropriate only for short-term benzodiazepine use (<3 months), not 15 years of continuous use. 7
Do not abruptly discontinue or use rapid taper without psychological support—this dramatically increases relapse risk (hazard ratio 2.09–2.97). 7
Do not misinterpret withdrawal symptoms as relapse and restart benzodiazepines—this perpetuates dependence. 6, 7
Avoid concomitant use of opioids or other CNS depressants during the taper due to risk of profound sedation and respiratory depression. 1
Expected Outcomes
With proper slow taper and psychological support, 68–75% of long-term benzodiazepine users can successfully discontinue within 4–6 months. 2, 7
Most patients who successfully discontinue maintain improvement in anxiety levels and general well-being during follow-up. 2
The patient's current low therapeutic dose (1 mg nightly) is favorable—most long-term users maintain or decrease their initial dose over time rather than escalating. 11